Concur: Overall survival (OS)
Primary endpoint
1.00
0.75
0.50
0.25
0.00
0
100
200
300
400
500
600
OS probability
Days from randomization
Events,
n
(%)
95 (69.9)
60 (88.2)
Median, months
8.8
6.3
HR [95% CI]
0.550 [0.395 ‒ 0.765]
P
= 0.0002 (1-sided)
Regorafenib
(
n
=136)
Placebo
(
n
=68)
45% reduction in risk of death
in the regorafenib group
J. Li, et al. WCGI 2014. Abstract O-0023. Presented at WCGI 2014, Barcelona, Spain
